The effect of Diprivan (propofol) on phosphorylcholine surfaces during cardiopulmonary bypass — an in vitro investigation

Perfusion

Volumn 24, Issue 5, 2009, Pages 349-355

  Myers, Gerard J ^a   Voorhees, Cheri ^b   Eke, Bob ^b   Johnstone, Renren ^b  

^a IWK HEALTH CENTRE   (Canada)

^b Cobe Cardiovascular Research Laboratory ^*  (United States)

Author keywords

cardiopulmonary bypass; Diprivan; oxygenator; phosphorylcholine; propofol

Indexed keywords

OXYGEN; PHOSPHORYLCHOLINE; PROPOFOL;

ADSORPTION; ADULT; ARTICLE; CARDIOPULMONARY BYPASS; CHEMISTRY; DRUG EFFECT; EXTRACORPOREAL OXYGENATION; HUMAN; METABOLISM; RANDOMIZATION; SURFACE PROPERTY;

ADSORPTION; ADULT; CARDIOPULMONARY BYPASS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; OXYGEN; PHOSPHORYLCHOLINE; PROPOFOL; RANDOM ALLOCATION; SURFACE PROPERTIES;

EID: 77950358587     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659109353819     Document Type: Article

References (19)

1. Rosen DA, Rosen KR, Silvasi DL, et al. In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth 1990; 4: 332-336
2. Booth BP, Henderson M., Milne B., et al. Sequestration of glyceryl trinitrate (nitroglycerine) by cardiopulmonary bypass oxygenators. Anesth Analg 1991; 72: 493-497
3. Hynynen M., Hammaren E., Rosenburg P. Propofol sequestration within the extracorporeal circuit. Can J Anesth 1994; 41(7): 583-588
4. AstraZeneca Can Inc. Drug monograph. July 21, 2004
5. Hiraoka H., Yamamoto K., Okano N., et al. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Therapeut 2004; 75: 324-330
6. Cockshott ID, Douglas EJ, Plummer GF, et al. The pharmacokenetics of propofol in laboratory animals. Xenobiotica 1992; 22: 369-375
7. Tarr TJ and Kent AP Sequestration of propofol in an extracorporeal circuit. J Cardiothorac Anesth 1989; 3(Suppl 1): 75
8. Hammaren E., Rosenburg P., Hynynen M. Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro. Br J Anaesth 1999; 82(1): 38-40
9. Myers, GJ, Johnstone, D., Swyer, WJ, et al. Evaluation of Mimesys Phosphorylcholine (PC) coated oxygenators during cardiopulmonary bypass in adults. J Extracorp Techn 2003; 35(1): 6-12
10. Lopez MM, Kosk-Kosicka D. Entropy driven interactions of anesthetics with membrane proteins. Biochemistry 1997; 36: 8864-8872
11. Nader-Djalal N., Khadra WZ, Spaulding W., et al. Does propofol alter the gas exchange in membrane oxygenators. Ann Thorac Surg 1998 ; 66: 298-299
12. Takizawa E., Hiraoka H., Takizawa D., et al. Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass. Br J Anaes 2006; 96(2): 179-185
13. Mazoit JX, Samii K. Binding of propofol to blood components; implications for pharmacokenetics and for pharmacodynamics. Br J Clin Pharmacol 1999; 47: 35-42
14. Leslie K., Sessler DI, Bjorksten AR, et al. Mild hypothermia alters propofol pharmacokenetics and increases the duration of action of atracurium. Anesth Analg 1995; 80: 1007-1014
15. Dawson PJ, Bjorksten AR, Blake DW, et al. The effects of cardiopulmonary bypass on total and unbound concentrations of propofol and midazolam. J Cardiothorac Vasc Anesth 1997; 11(5): 556-561
16. Yoshitani K., Kawaguchi M., Takahashi M., et al. Plasma propofol concentration and EEG burst suppression ratio during normothermic cardiopulmonary bypass. Br J Anesth 2003; 90(2): 122-126
17. Hammaren E., Yli-Hankala A., Rosenberg P., et al. Cardiopulmonary bypass induced changes in plasma concentrations of propofol and in auditory evoked potentials. Br J Anesth 1996; 77: 360-364
18. Wood M. Plasma drug binding: implications for anesthesiologists. Anesth Analg 1986; 65: 786-804
19. Hickey S., Quasim I., Gaylor J. In vitro variability in propofol absorption by different membrane oxygenators. Crit Care 2001; 5(Supp C): 8